01—Abstract
Summary
Summary of the 8-K filed October 14, 2025. Cited figures are marked; the original filing is the authoritative source.
Johnson & Johnson reported third-quarter 2025 results for the period ended September 28, 2025, with reported sales of $23.99 billiona, up 6.8% year over year, and operational growth of 5.4% (adjusted operational growth of 4.4%, excluding acquisitions, divestitures and currency).
Reported diluted EPS was $2.12b, up 91%, but this was inflated by a large non-operating swing: other income of $478 million versus $1.8 billion of expense a year earlier, litigation-related charges of $2.4 billion in Q3 2024 that did not recur, and a $387 million gain on securities. Adjusted diluted EPS was $2.80, up 15.7%. Growth was led by Innovative Medicine (reported sales up 6.8% to $15.56 billion) with strong contributions from DARZALEX, CARVYKTI, TREMFYA and ERLEADA, offset by a roughly 1,070 basis-point drag from STELARA biosimilar erosion.
MedTech sales rose 6.8% to $8.43 billionc, led by electrophysiology, Abiomed and Shockwave. Management raised its full-year 2025 reported sales guidance to $93.5–$93.9 billion (midpoint $93.7 billion, up 5.7%) and kept adjusted EPS guidance at $10.80–$10.90 (midpoint $10.85), absorbing higher tax costs; the company noted an $874 million tax-related item in the quarter. Separately, Johnson & Johnson announced its intent to separate its Orthopaedics business, to be operated as a standalone company named DePuy Synthes with roughly $9.2 billion of FY2024 sales.
The transaction is targeted for completion within 18 to 24 months and remains subject to conditions, board approval and regulatory approvals, and there is no assurance of timing or structure. Namal Nawana was named Worldwide President of DePuy Synthes effective immediately.
For investors, the key takeaways are solid underlying top-line momentum in the pharmaceutical and surgical/cardiovascular franchises, a raised reported sales outlook, stable adjusted EPS guidance despite tax headwinds, and a portfolio-reshaping separation that management says will improve growth and margins in the remaining MedTech business. The separation is still early-stage, and near-term results will continue to be affected by STELARA erosion and the timing of the separation.
02—Key points
Key Highlights
- Reported Q3 2025 sales of $23.99B, up 6.8%; operational growth 5.4% and adjusted operational growth 4.4%.
- GAAP diluted EPS of $2.12 (up 91%) and adjusted diluted EPS of $2.80 (up 15.7%); the GAAP jump largely reflects the absence of a $2.4B litigation charge in Q3 2024 and a $387M securities gain in Q3 2025.
- Innovative Medicine sales rose 6.8% to $15.56B, led by DARZALEX, CARVYKTI, TREMFYA and ERLEADA, partly offset by STELARA erosion of about 1,070 basis points.
- MedTech sales rose 6.8% to $8.43B, driven by electrophysiology, Abiomed, Shockwave and Surgery/Vision.
- Full-year 2025 reported sales guidance raised to $93.5–$93.9B (midpoint $93.7B, up 5.7%); adjusted EPS guidance reaffirmed at $10.80–$10.90, absorbing higher tax costs.
- Announced intent to separate the Orthopaedics business as a standalone company, DePuy Synthes (~$9.2B FY2024 sales), targeted for completion within 18–24 months, subject to conditions and approvals.
- Q3 Free cash flow was estimated at about $14.2B for the quarter (versus $14.5B in the prior-year quarter), with operating cash flow to be disclosed in later SEC filings.
03—Questions
Frequently Asked Questions
Why did reported EPS rise 91% if adjusted EPS only rose 15.7%?
The GAAP comparison is distorted by prior-year items. Q3 2024 included a roughly $2.4 billion pre-tax litigation charge and a higher tax rate, while Q3 2025 benefited from a $387 million gain on securities and lower other expense. Adjusted EPS strips out intangible amortization, litigation, restructuring and other special items, so it better reflects underlying earnings growth of about 15.7%.
Did J&J change its full-year outlook?
Partly. Reported sales guidance was raised to $93.5–$93.9B (midpoint $93.7B, up from $93.4B). Adjusted operational sales guidance was raised to 3.5%–4.0% growth, and adjusted EPS guidance was unchanged at $10.80–$10.90, as management absorbed higher tax costs, including an $874 million tax-related item in Q3.
What is the Orthopaedics separation and what does it mean for shareholders?
J&J plans to spin off or otherwise separate its Orthopaedics business as DePuy Synthes, a standalone company with about $9.2B of FY2024 sales. Management says the move will sharpen focus on higher-growth MedTech areas (Cardiovascular, Surgery, Vision) and improve growth and margins. The transaction is targeted for 18–24 months and is not guaranteed in timing or structure, and the filing does not quantify expected financial impact or the form of consideration.
What is the biggest risk to J&J's pharmaceutical growth?
The most visible headwind is the erosion of STELARA following biosimilar competition, which subtracted roughly 1,070 basis points from Innovative Medicine operational growth in Q3. Growth depends on offsetting this with newer products such as TREMFYA, DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE, as well as pipeline milestones like the icotrokinra filing.
How strong is J&J's cash generation this quarter?
The company estimated Q3 year-to-date free cash flow at about $14.2B, slightly below the prior-year quarter's $14.5B. Free cash flow is a non-GAAP measure defined as operating cash flow less capital expenditures, and the GAAP operating cash flow figure was to be disclosed in subsequent SEC filings, so the filing does not provide a complete GAAP cash flow picture.
04—Continue